Phase 3 Front-MIND Trial Initiated to Explore Tafasitamab Triplet in DLBCL
June 16th 2021A phase 3 trial has been initiated to explore the potential of a triplet regimen of tafasitamab-cxix, lenalidomide, and R-CHOP as a treatment options for patients with newly diagnosed diffuse large B-cell lymphoma.
In R/R B-NHL, High Marks Achieved by C-CAR066
June 8th 2021A favorable safety profile and promising efficacy was seen with C-CAR066, a novel 2nd generation chimeric antigen receptor T-cell therapy targeting the CD20 antigen, in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.
Nivolumab Plus Chemotherapy Shows Significant Improvements in Resectable NSCLC
June 6th 2021Data presented at the 2021 virtual ASCO Annual Meeting showed the benefits of adding nivolumab to chemotherapy treatment compared to chemotherapy alone, in patients with resectable non-small cell lung cancer.